Financials data is unavailable for this security.
View more
Year on year IPCA Laboratories Ltd grew revenues 23.39% from 62.44bn to 77.05bn while net income improved 16.13% from 4.71bn to 5.47bn.
| Gross margin | 67.08% |
|---|---|
| Net profit margin | 6.84% |
| Operating margin | 10.27% |
| Return on assets | -- |
|---|---|
| Return on equity | -- |
| Return on investment | -- |
More ▼
Cash flow in INRView more
In 2024, cash reserves at IPCA Laboratories Ltd fell by 8.23bn. However, the company earned 10.21bn from its operations for a Cash Flow Margin of 13.25%. In addition the company used 12.92bn on investing activities and also paid 5.53bn in financing cash flows.
| Cash flow per share | 37.40 |
|---|---|
| Price/Cash flow per share | 38.68 |
| Book value per share | -- |
|---|---|
| Tangible book value per share | -- |
More ▼
Balance sheet in INRView more
| Current ratio | -- |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | -- |
More ▼
Growth rates in INR
Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items increased 16.13%. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 0.39% |
|---|---|
| Div growth rate (5 year) | 21.67% |
| Payout ratio (TTM) | 0.00% |
| EPS growth(5 years) | 4.15 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 17.46 |
More ▼
